Tuesday's Daily Dose: Potential lung cancer breakthrough, a warning about unprescribed Adderall use, and sports center for women

A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
The Malaysian Reserve

FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational ...